Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag, DAM Heideman… - European journal of …, 2011 - Elsevier
BACKGROUND: Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
(EGFR) are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an …
[引用][C] Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag, DAM Heideman… - European Journal of …, 2011 - cir.nii.ac.jp
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with
NSCLC who initially responded to EGFR-TKI treatment | CiNii Research CiNii 国立情報学研究所 …
NSCLC who initially responded to EGFR-TKI treatment | CiNii Research CiNii 国立情報学研究所 …
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag, DAM Heideman… - European Journal of …, 2011 - infona.pl
Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are approved
as treatment of non-small-cell lung cancer (NSCLC). Despite an initially impressive …
as treatment of non-small-cell lung cancer (NSCLC). Despite an initially impressive …
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag, DAM Heideman… - European Journal of …, 2011 - ejcancer.com
Background Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR)
are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially …
are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially …
[引用][C] Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag… - European …, 2011 - researchinformation.amsterdamumc …
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with
NSCLC who initially responded to EGFR-TKI treatment — Amsterdam UMC research portal Skip …
NSCLC who initially responded to EGFR-TKI treatment — Amsterdam UMC research portal Skip …
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
A Becker, L Crombag, DA Heideman… - European Journal of …, 2011 - europepmc.org
Background Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR)
are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially …
are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially …
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag… - … journal of cancer …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR)
are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially …
are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially …
[PDF][PDF] Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment
A Becker, L Crombag, DAM Heideman… - EUROPEAN …, 2011 - academia.edu
Background: Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR)
are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially …
are approved as treatment of non-small-cell lung cancer (NSCLC). Despite an initially …